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RESUMO – A disqueratose congénita é uma síndrome hereditária multissistémica, com manifestações clínicas e genéticas hete-
rogéneas, caracterizada como uma doença dos telómeros, causando seu encurtamento precoce. É uma condição rara, com uma 
incidência anual estimada de 1 em 1 milhão de indivíduos. É mais comum em homens, com uma proporção aproximada de 3,2:1. 
As principais manifestações clínicas precoces são despigmentação cutânea, distrofia ungueal e anormalidades na orofaringe, ocor-
rendo geralmente entre cinco e doze anos de idade. A insuficiência da medula óssea é a principal causa de morte, mas existem 
outras complicações sistêmicas.
Apresentamos um relato de caso de uma criança do sexo feminino de dois anos de idade, que apresentou sinais e sintomas mu-
cocutâneos cardinais de DC em idade precoce, e enfatizamos a importância de um monitoramento multidisciplinar do paciente.
PALAVRAS-CHAVE – Disqueratose Congénita; Telómeros.
Dyskeratosis Congenita and Short Telomeres in a 
Female Patient    
ABSTRACT – Dyskeratosis congenita (DC) is a hereditary and multisystemic syndrome, with heterogeneous clinical and genetic ma-
nifestations, characterized as a disease causing its early shortening of the telomeres. It is a rare condition, with an estimated annual 
incidence of 1 in 1 million individuals. It is more common in males, with an approximate ratio of 3.2:1. The main early clinical features 
are a characteristic cutaneous dyspigmentation, nail dystrophy and abnormalities in the oropharynx, usually occurring between five 
and twelve years of age. Bone marrow failure (BMF) is the leading cause of death but there are other systemic complications. 
We present a case report of a two-years-old female child, who presented the cardinal mucocutaneous signs and symptoms of DC at 
an early age, and we emphasize the importance of a multidisciplinary patient monitoring. 
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INTRODUCTION
Dyskeratosis congenita (DC) is a rare genetic disease 
that affects more males and presents with typical cutaneous 
and systemic signs, such as the mucocutaneous triad (dys-
pigmentation, nail dystrophy, leukoplakia). We present a 
case in a female patient, who already presented the typical 
signs at 2 months of age (below the median age reported in 
the literature - 14 years of age)1 as well as atypical patterns 
of progression of onychodystrophy and adermatoglyphia 
and positive result for short telomeres.
CASE REPORT
A 2-years-old female child, the second daughter of non-
-consanguineous parents, born by cesarean delivery after an 
uneventful pregnancy, was observed with reticulated hyperpig-
mentation and hypochromic areas in the face (nasal dorsum, 
upper lip and lower eyelids), cervical region, armpits, inguinal 
region, hands (back and palm) and dorsum of the feet. She 
also had nail dystrophy in the toes, not in the fingers, but here 
we could observe adermatoglyphia affecting all the fingers. 
There was also a 2 x 1.5 cm plaque of oral leukoplakia in 
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the papillary tongue (Fig.s 1, 2 and 3). These skin lesions had 
started at the age of two months. She presented also a minor 
speech delay, but no alterations in other development para-
meters. There are no other complaints and the parents denied 
similar cases in the family. Biochemical tests were normal. The 
investigation of the telomeric length of leukocytes in peripheral 
blood, carried out in the laboratory of the Hospital das Clíni-
cas, Faculdade de Medicina de Ribeirão Preto, São Paulo state, 
Brazil, showed a telomer length below the expected range for 
the patient´s age (short telomere), corroborating the diagnosis 
of dyskeratosis congenita. Currently, the patient is six years old 
and has developed no further complications during the multi-
disciplinary follow-up and there was no progression in the area 
of leukoplakia or dyspigmentation. She does not show any dis-
comfort or social damage regarding the skin manifestations. 
The parents are well informed and involved in the care of their 
daughter but they chose not to perform genetic evaluation.
DISCUSSION
DC was first described in 1906 by Zinsser, and then cha-
racterized as a clinical entity in 1926 by Engman and Cole, 
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Figure 1 - Hands and feet showing bilateral reticulated hyperpigmentation. Onychodystrophy is evident in the feet, being more severe in the right 
foot. Bilateral adermatoglyphia is also evident on the hands. 
Figure 2 - Reticulated hyperpigmentation in the neck and armpit. 
Figure 3 - Oral leukoplakia on the papillary surface of the tongue 
measuring approximately 2 x 1.5 cm.  
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thus it became known as the Zinsser-Cole-Engman syndro-
me.2,3 Since 1998, at least eleven genes associated with DC 
have been recognized, with nine of them related to mainte-
nance of the length of the telomeres. The inheritance patterns 
of DC are X-linked-recessive (XLR) for the DKC1 gene, autoso-
mal dominant (AD) for TERC, TERT, TINF2, RTEL1 and ACD and 
autosomal recessive (AR) for TERT, NOP10, NHP2, WRAP53, 
CTC1, USB1, RTEL1 and ACD.2-4 The most common mutation 
is in DKC1, which explains, in part, the trend towards males 
(approximate ratio of 3.2:1).2,6,7 However, about 30% to 40% 
of patients may not have an identifiable mutation in the ge-
netic evaluation.5 The clinical features of DC are highly varia-
ble, even within families with the same mutation, with variable 
penetrance and phenotypic differences. The estimated annual 
incidence is 1 in 1 million individuals.2,6,7
The classic clinical presentation of DC starts at around five 
to twelve years of age, characterized by the mucocutaneous 
triad: abnormal skin pigmentation, nail dystrophy and oral 
leukoplakia. Shimamura et al (2010) evaluated 550 reports 
published from 1910 to 2009. The age at diagnosis range 
from 0 to 75 years, but was mostly between 0 to 30 years, with 
median age of onset at 14 years.1 Skin changes occur in ap-
proximately 90% of patients as reticulated hyperpigmentation 
in different body regions. Nail dystrophy is present in about 
90% of patients, with a tendency to involve initially the fin-
gernails and later toenails.4 Other skin changes include cuta-
neous atrophy, hyperhidrosis and hyperkeratosis of the palms 
and soles, telangiectasia, cracking, fissuring, bullae and loss 
of dermal ridges.8 Epidermal atrophy, basal cell degeneration 
and increased melanophages are found in histopathology.9
Oral leukoplakia, the most specific clinical manifestation, 
affects about 80% of DC patients, and involves the tongue, 
oral mucosa and oropharynx. Malignant transformation oc-
curs mostly in areas of leukoplakia: squamous cell carcino-
ma (SCC) occurs in about 30% of individuals within 10 to 30 
years.3 Severe periodontal destruction, gingival inflammation, 
bleeding and bone loss are other significant associations. 
The patient in this report has the typical DC triad of leuko-
plakia, hyperpigmentation in the classic regions and onycho-
dystrophy was significant on the feet, not on the hands, 
contrasting with the usual DC trend. Adermatoglyphia, ano-
ther potential finding in DC, was evident on all fingers (Fig.s 
1, 2 and 3).
Bone marrow failure (BMF) is the leading cause of death 
in 60% to 80% of patients.2,3 It usually starts before the age 
of 20, and approximately 90% of patients have this symptom 
by the age of 30.10 The progressive shortening of telomeres 
with repeated cell divisions reaches its critical threshold and, 
thereafter, cell proliferative capacity becomes limited. Tissues 
with a high proliferative rate, such as hematopoietic, mucosa 
and epithelium, are mainly affected.1 In about 90% of patients 
BMF initially presents as gradual thrombocytopenia, before 
developing peripheral cytopenia in other hematological linea-
ges.3 Hematological changes were not evident in this patient, 
as would be expected at this age, but periodic hematological 
follow-up is mandatory for early identification of BMF. 
Malignancy and pulmonary disorders are other important 
complications in the adult with DC. Telomere shortening may 
be associated with chromosome instability, which promotes 
tumorigenesis.3 The cumulative incidence of malignancy is 
around 40% to 50% at 50 years of age. The most common 
tumors are SCC of the skin, tongue, larynx and bronchial 
tree, in addition to leukemia, with or without previous mye-
lodysplastic syndrome, and adenocarcinoma of the gastroin-
testinal tract.2,3 Pulmonary fibrosis, present in about 80% of 
adult patients due to the high rate of pulmonary epithelium 
losses, causes difficulties in gas exchange and abnormalities 
in pulmonary vascularization and is also an important cause 
of mortality.3 The patient in this case undergoes periodic der-
matological and non-invasive pulmonary monitoring, using 
techniques such as spirometry, to avoid exposure to x-rays 
due to the increased risk of neoplasia. 
DC may cause multisystemic defects in varying aspects, 
including: development delay; microcephaly; ophthalmo-
logical abnormalities; premature aging; lung disease; he-
patic cirrhosis; hypogonadism and malignancy; alopecia; 
and premature fatigue.7 DC has two clinical variants, Re-
vesz syndrome and Hoyeraal-Hreidarsson syndrome (HHS), 
differing in severity. The classic symptoms of DC, such as 
mucocutaneous manifestations and BMF, are common for 
both syndromes; however, both have serious deficiencies in 
other systems. Revesz syndrome is associated with intraute-
rine growth retardation, psychomotor retardation, bilateral 
exudative retinopathy, cerebral calcification and cerebellar 
hypoplasia. Hoyeraal-Hreidarsson syndrome is associated 
with intrauterine growth retardation, severe mental retarda-
tion, immunodeficiency and pancytopenia.
The diagnosis of DC is made when at least two major 
and two minor criteria are present.3 The major criteria are 
the three components of the mucocutaneous triad and BMF. 
The minor criteria include components associated with mul-
tisystem disorders: epiphora, development delay, periodon-
tal disease, esophageal stenosis, premature aging or hair 
losses and development of malignant lesions. Telomere shor-
tening is not specific to DC, but telomere size has a sensiti-
vity of 97% and specificity of 91% when it is below the first 
percentile in lymphocytes for the patient´s age.3 The patient 
in this case has three major criteria (onychodystrophy, reti-
culated hyperpigmentation and oral leukoplakia), one minor 
criterion (delay in speech development) and an examination 
showing telomeres below the first percentile for her age. The 
most relevant differential diagnoses associated with telomere 
shortening are Shwachman-Diamond syndrome and Fanco-
ni anemia. Fanconi anemia frequently presents with pancyto-
penia, café au lait, hyper- or hypopigmentation areas, and 
has a strong association with endocrinological abnormali-
ties. Shwachman-Diamond syndrome often presents with 
neutropenia and intestinal malabsorption due to pancreatic 
insufficiency. In both cases short stature is common.1 
BMF is treated according to the degree of cytopenia and 
does not respond adequately to immunosuppressive thera-
py.2 Hematopoietic stem cell transplantation (HSCT) is the 
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existing curative modality for BMF.11 Androgens such as oxy-
metholone and danazol may be a therapeutic alternative, 
as they possibly interfere with erythropoiesis, stimulating he-
matopoietic stem cells and modulating telomerase.3 Danazol 
has fewer adverse effects, especially with regard to the mas-
culinization of women.3 
The management of dermatological changes involves 
prevention and symptomatic treatment: photoprotection to 
reduce the risk of skin malignancy,  keratolytic agents, to 
soften hyperkeratosis, moisturizers to improve dry skin in re-
gions with poikiloderma and cutaneous atrophy.5 The mana-
gement of nail changes aims to prevent accidental injuries 
during daily activities, but there is no specific treatment for 
onychodystrophy in these cases. The patient must reduce ex-
cessive exposure to detergents and other irritants, avoiding 
prolonged use of artificial nails, and must periodically polish 
them to reduce discomfort and possible accidents. The use 
of biotin can help to strengthen brittle nails. Good dental 
hygiene may help prevent early dental loss and delay the 
development of malignancy of the tongue.5
Laser therapy, such as carbon dioxide laser, is effective in 
treating oral leukoplakia.2 Surgical excision is curative form 
for most malignant lesions without metastasis, but radio-
therapy and chemotherapy agents are not recommended.1 
Therefore, prevention is important by avoiding exposure to 
potentially carcinogenic substances, such as alcohol, tobac-
co, and also by vaccination for the human papiloma virus 
(HPV).5
Genetic testing of the patient and relatives and genetic 
counseling is important to help the patient and her family to 
have a more realistic perspective about the disease expecta-
tions and limitations. If the patient has a de novo mutation 
and parents do not have mutations, the chances of having 
another child with DC are low.5
CONCLUSION
Patients with DC should receive periodic multidisciplinary 
follow-up to identify and treat early the multisystemic com-
ponent and potential lifelong complications. This report des-
cribes a female patient who developed early mucocutaneous 
manifestations and telomere length below the first percentile 
for her age, corroborating the diagnosis of DC, but still no 
other manifestations by the age of six years old.
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